G protein-coupled receptor 31Genealiases: 12-HETER · HETER · HETER1
Q-omics provides the consensus-scored GPR31 profile across patient tissues and cancer cell-line models. GPR31 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, GPR31 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, GPR31 protein abundance shows 24,413 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight SKCM, KIRC, and UCEC as cancer lineages where GPR31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR31 survival associations across molecular data types. GPR31 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR31 RNA expression–survival associations across cancer types. High GPR31 expression shows unfavorable associations in UVM and LGG, but favorable associations in SKCM, LUAD, HNSC and SCLC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for GPR31 RNA expression.
This table summarizes GPR31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for GPR31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR31 shows lower tumor expression in UCEC and COAD and higher tumor expression in KIRC, BRCA, STAD and LUAD. The KIRC box plot shows higher GPR31 RNA expression in tumor versus normal tissue (log2 FC = +0.267, t-test p < 0.001).
This table shows molecular features associated with GPR31 in patient tissues and cancer cell lines. In patient samples, GPR31 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR31 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
